Treatment with combined immune checkpoint blockade (CICB) agents targeting both CTLA-4 and PD-1 has demonstrated remarkable clinical efficacy across various tumor types; however, this efficacy comes at the cost of frequent, severe immune-related adverse events 209. Here, CTLA4 is linked to neoplasm.